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PRACTICAL AND COMPREHENSIVE GUIDELINES
FOR BEDSIDE CEREBRAL HEMOMETABOLIC
MULTITHERAPEUTIC OPTIMIZATION
Julio Cruz1
ABSTRACT - In recent years, noncomprehensive “guidelines” were proposed for the management of severe
acute brain injuries, focusing strictly on two approaches: 1) to maintain cerebral perfusion pressure anywhere
above 70 mm Hg; and 2) to maintain arterial carbon dioxide tension levels above 30 torr. Strictly following
these propositions, a recently reported prospective controlled study addressed mortality rates of no less than
75-76%, far worse than mortality rates reported before those “guidelines” were published. As a humanitarian
alternative, the present comprehensive guidelines are aimed at addressing practical bedside strategies to
manage no only intracranial pressure and cerebral perfusion pressure but also cerebral extraction of oxygen,
based on solid previously reported papers which revealed the lowest mortality rates (below 15%) in the
pertinent literature, in recent years.
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Diretrizes práticas e abrangentes para otimização hemometabólica cerebral multiterapêutica
RESUMO - Em anos recentes, “diretrizes” não abrangentes foram propostas para o tratamento de traumatismos
cerebrais agudos graves, enfocando estritamente em duas abordagens: 1) manter-se a pressão de perfusão
cerebral em quaisquer níveis acima de 70 mm Hg; e 2) manter-se a pressão parcial de gás carbônico arterial
acima de 30 torr. Seguindo estritamente tais proposições, artigo recentemente publicado envolvendo estudo
prospectivo controlado revelou taxas de mortalidade de não menos que 75-76%, muitissímo piores do que
taxas de mortalidade publicadas anteriormente a essas “diretrizes”. Como uma alternativa humanitária, as
diretrizes aqui propostas têm como meta explicar estrategias para que se tratem não apenas a pressão
intracraniana e a pressão de perfusão cerebral, mas também a extração cerebral de oxigênio, baseando-se em
trabalhos sólidos publicados anteriormente, os quais revelaram as menores taxas de mortalidade (inferiores a
15%) da literatura pertinente, em anos recentes.
PALAVRAS-CHAVE: extração cerebral de oxigênio, pressão intracraniana, diretrizes, traumatismo cerebral.
Back in 1996, “guidelines” for the management
of severe acute brain injuries were published by
several authors and were said to be “evidence-ba-
sed”1. This was not true, however, because no less
than four strictly relevant previously published pa-
pers2-5 were omitted from citation and discussion in
those “guidelines”, despite the fact that those four
papers had been published in leading international
medical journals. Therefore, those “guidelines”1 were
biased and not truly evidence-based, as would have
been required in a publication of that kind.
Strictly following those 1996 “guidelines”1, a
recently published prospective controlled study6 fo-
cusing on the use of induced hypothermia addressed
mortality rates of no less than 75-76%, far worse
than low mortality rates2-4 reported before the afore-
mentioned 1996 “guidelines” were published. In this
recent study6, routine attempts were made to avoid
hyperventilation therapy, maintaining arterial carbon
dioxide tension (PCO2) levels above 30 torr and cere-
bral perfusion pressure (CPP) anywhere above 70 mm
Hg, in addition to frequent mannitol administration
and barbiturate therapy for all patients, supple-
mented by induced hypothermia for the study group.
As a humanitarian alternative to those 1996
“guidelines”1, the present practical and comprehen-
sive guidelines address not only treatment of intrac-
ranial pressure (ICP) and CPP but also cerebral ex-
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traction of oxygen (CEO2)
2,4,7-12. The latter represents
the ratio of global cerebral consumption of oxygen
(CCO2) to cerebral blood flow (CBF)
8, and thus pro-
vides accurate bedside information regarding cou-
pling or uncoupling between CBF and CCO2. Ad-
equate CBF-CCO2 coupling, in turn, has already been
reported in association with significantly better long-
term clinical outcomes from severe acute brain inju-
ries than when a flow-metabolism uncoupling ex-
ists during the acute phase of illness9,13.
Of these two latter studies, the first was based
on purely observational (noninterventional) clinical
research13, whereas the second addressed a large
prospective controlled trial involving 353 adult pa-
tients9. In the latter series, patients were selected
for having predominantly diffuse brain swelling and
early intracranial hypertension for both groups, and
the use of optimized hyperventilation was conclu-
sively confirmed in association with significantly
better long-term clinical outcomes than in the con-
trol group, where CPP was managed alone (without
the use of optimized hyperventilation therapy)9.
ICP and CPP
A frequently neglected feature in the mana-
gement of acute brain injuries is that normal ICP is
approximately 5 and 10 mm Hg only for children
and adults, respectively. Therefore, the present gui-
delines propose that elevated ICP levels be aggres-
sively treated so that they are maintained below 15
and 20 mm Hg for children and adults, respectively.
Additionally, instead of maintaining CPP anywhere
above a certain level, the present guidelines propose
maintaining CPP in the approximate ranges of 50-
80 and 60-95 mm Hg for children and adults, re-
spectively.
Indeed, normal-to-increased CPP (the difference
between mean arterial pressure and mean ICP) has
been clearly shown to totally lack any correlation
with CBF, oxygen extraction, and oxygen consump-
tion in severe acute brain injuries5. This recently re-
ported, striking finding therefore strongly indicated
that maintaining high CPP levels leads to absolutely
no clinical benefit, insofar as physiological opti-
mization is concerned, based on mistaken therapies
that iatrogenically increase the blood pressure. Fur-
thermore, as early as 1968, it has been well demon-
strated experimentally that arterial hypertension does
worsen traumatic brain swelling14. This original ani-
mal study thus suggested that artificially maintain-
ing high CPP levels (as proposed in the 1996 “guide-
lines”1) may, in fact, lead to catastrophic consequen-
ces when managing brain-injured patients with de-
creased cerebrospinal fluid spaces and elevated ICP.
CEO2, CCO2, and CBF
CEO2 is simply the arteriojugular oxyhemoglobin
saturation difference, and represents one of several
novel parameters that we have previously proposed
for bedside assessment of cerebral hemometabo-
lism2,4,7-12. Because CEO2 is the ratio of CCO2 to CBF,
it then becames clear that CCO2 and CBF need not
be measured, because CEO2 alone accurately informs
about coupling or uncoupling between CBF and
CCO2
8,9.
The normal CEO2 ranges are 17-35% and 24-42%
for children and adults, respectively2,4,8-12. For the-
rapeutic purposes, the target values are the normal
means of 26% and 33%, respectively. These ranges
should be used for therapeutic maintenance (besides
maintaining the aforementioned ranges for ICP and
CPP), whenever possible. Normal-to-increased CEO2
values are indicative of relative cerebral hypoper-
fusion, where CBF is reduced relative to CCO2. Un-
der these circumstances, attempts should be made
to increase CBF and decrease CEO2, however with-
out compromising adequate ICP control. Conversely,
normal-to-decreased CEO2 values are indicative of
relative cerebral hyperperfusion, where CBF is high
relative to CCO2. Under these circumstances, if ICP is
mildly or more markedly elevated, attempts should
be made to decrease CBF and increase CEO2, ideally
without exceeding the upper normal CEO2 limit.
Optimized nonbarbiturate sedation
This is the first step for cerebral hemometabolic
optimization, which also allows for adequate mecha-
nical ventilation. In recent years, midazolam has been
the most frequently used drug, sometimes in com-
bination with fentanyl for concomitant analgesia.
The effects of both drugs on CEO2 are not yet known,
but their use can be titrated to maintain normal ICP,
CPP, and CEO2 as well. The main side effect of this
treatment modality is arterial hypotension, which can
be reversed by decreasing the administered doses.
Expectedly, CEO2 could increase if arterial hypoten-
sion decreases CBF relative to CCO2. Conversely, CEO2
could also remain normal, because sedation may
decrease CCO2 as well. Therefore, directly measur-
ing CEO2 is the best way of evaluating potential side
effects or benefits of nonbarbiturate intravenous
sedation.
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Optimized mannitol
Because we also monitor CEO2 (instead of ICP and
CPP alone), it then became possible to define an
optimal use of intravenous mannitol. This is because,
based on ICP alone, the repetitive use of mannitol
may lead to hyperosmolality, hypovolemia, and even
acute renal failure in extreme cases. Indeed, we have
previously reported that the best indication for
mannitol is when elevated ICP is associated with nor-
mal-to-increased CEO2 (relative cerebral hypoper-
fusion)7. Under these conditions, fast intravenous
mannitol not only lowers elevated ICP but also de-
creases the CEO2 toward normal levels, indicative of
adequate therapeutic restoration of global CBF-CCO2
coupling7. These positive effects are because, as pre-
viously reported15, CBF does increase following man-
nitol administration.
The use of nonoptimized mannitol (with normal-
to-decreased CEO2, or relative cerebral hyperperfu-
sion) may also be adopted, but only as long as a
sustained benefit regarding ICP control can be con-
firmed. Nonoptimized mannitol administration
should be discontinued if its effect on ICP control
lasts less than two hours. The usual mannitol dose
for fast intravenous infusion is in the range of 0.4-
0.7 g/kg, but higher doses could also be considered,
especially in the event that abnormal pupillary
widening is found, and/or in preparation for decom-
pressive surgery (see later).
Optimized hyperventilation
Also because we monitor CEO2 (instead of ICP
and CPP alone), it was possible to first propose the
use of optimized hyperventilation. The latter is in-
dicated in an opposite fashion to that of optimized
mannitol; that is, optimized hyperventilation is used
for elevated ICP and normal-to-decreased CEO2, or
relative cerebral hyperperfusion2,4,9-12. As a general
rule, optimized hyperventilation is instituted with
arterial (or expired) PCO2 levels in the approximate
range of 20-30 torr, and is implemented for variable
periods of no less than 3-4 days. Some patients with
more challenging ICP problems will require optimized
hyperventilation for longer periods.
According to these standards, when normal ICP
levels are achieved, and after at least 4-5 days, PCO2
values of 30 torr or slightly higher should be gradually
restored by slowly reversing the process of optimized
hyperventilation, but only as long as normal ICP levels
are maintained. In our experience, ICP, CPP, and CEO2
monitoring and management have lasted appro-
ximately 7-10 days for both adults2,4,9,11 and chil-
dren12, according to our comprehensive treatment
protocol. This is in sharp contrast to approximately
18 + 13 days reported by those who did not hyper-
ventilate the patients, and iatrogenically induced CPP
values anywhere above 70 mm Hg16.
Optimized barbiturate therapy
Also based on CEO2 and jugular oxyhemoglobin
saturation (SjO2) monitoring, we
17 first demonstrated
that, immediately following intravenous bolus injec-
tions of barbiturates for the treatment of elevated
ICP refractory to ongoing optimized mannitol and
optimized hyperventilation, blood pressure may fall,
along with SjO2 decreases (CEO2 increases) in some
patients. Therefore, caution should be exercised whe-
never intravenous barbiturate boluses are adminis-
tered for ICP control, and the use of vasopressor
drugs should be immediately instituted if necessary.
The usual barbiturate dose (pentobarbital or thio-
pental) is approximately 15 mg/kg for the loading do-
se over 60-90 minutes, followed by approximately
1.5-2 mg/kg/hour for the maintenance dose. With
normal and stable ICP levels for at least 24 hours, the
cumulative use of optimized mannitol, optimized hy-
perventilation, and optimized barbiturate therapy can
then be gradually discontinued in the reverse order of
implementation, starting with barbiturate discon-
tinuation. The latter is usually accomplished by de-
creasing the infusion dose by 50% at intervals of ap-
proximately 6 hours. Discontinuing the cumulative
treatment protocol9-12 should be considered no earlier
than at least 4-5 days after the start of treatment. When
instituting barbiturate therapy if necessary, it is ob-
vious that the first step of the protocol (nonbarbi-
turate intravenous sedation) should be discontinued.
Decompressive surgery
Having optimized and maximized the above-de-
scribed nonsurgical cumulative treatment protocol,
as gradually or rapidly as required by less or more
challenging ICP problems, decompressive surgery
should then be considered for refractory intracra-
nial hypertension (ideally before ICP exceeds 30 mm
Hg). The choice of external versus internal decom-
pression depends on the presence or absence of brain
areas that are presumably unviable (e.g., hemor-
rhagic contusions), as well as the neurosurgeon’s
experience. We have successfully adopted decom-
pressive surgery11,12,18,19 as the final step in the cu-
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mulative treatment protocol that we developed over
the years, and for a large number of patients.
Comparative clinical outcomes
According to our previously reported treatment
protocol, the best mortality rates have ranged from
9% (for comatose adult patients with predominantly
traumatic diffuse brain swelling)9 to 14% (for coma-
tose adult patients with acute subdural hematomas
and postoperative brain swelling)11. For selected chil-
dren in acute coma with traumatic intracranial hy-
pertension, our treatment protocol was associated
with a mortality rate of 4% only12. These figures are
in sharp contrast to 75-76% mortality rates6 reported
for adult patients treated according to the above-
mentioned 1996 “guidelines”1, and strongly indicate
that our presently proposed comprehensive guide-
lines are far more humanitarian and clinically sound
than any other previously reported.
Abandoning brain tissue probes
A recent study20 involving sophisticated nonin-
vasive positron emission tomography has definitively
ruled out the occurrence of regional brain ischemia
following hyperventilation therapy, a finding in full
agreement with our previously reported global (arte-
riojugular) measurements involving both oxygen and
glucose extraction2,4. Indeed, we have also recently
reported that global brain ischemia is absolutely rare
in acute brain trauma, as evaluated by simultaneous
arteriojugular oxygen and lactate differences11.
Despite the above-mentioned findings, an alter-
native monitoring “modality” involving acute place-
ment of brain tissue probes to evaluate focal oxygen
tension21 has claimed that hyperventilation is harm-
ful. In this recent paper21, the authors found that even
when the jugular catheter showed high cerebral ve-
nous oxygenation, hyperventilation dropped the brain
tissue oxygen tension to so-called “critically low” le-
vels. In this respect, however, it is well known that
acute placement of brain tissue probes causes focal
microvascular compression and distortion, besides
focal blood-brain barrier disruption (because the
probes are too stiff relative to the soft brain tissue).
Therefore, it is not surprising that brain tissue
probes will almost invariably show low oxygen va-
lues, which are, nevertheless, just focal and artifac-
tual relative to the global brain. The latter is better
evaluated by techniques where the brain tissue is
not invaded (e.g., jugular measurements or positron
emission tomography). Furthermore, because healthy
human beings will just never volunteer to have their
heads open for any brain tissue probe to be placed,
normal physiological values for these probes designed
for any “measurement” (e.g., microdialysis, oxygen
tension, temperature, etc) are not even known, and
most likely will never be known. Therefore, “critical”
values for any element measured by these focal brain
tissue probes represent speculation and misinforma-
tion, at least until otherwise proven.
Because normal physiological values are not even
known, and because these focal brain tissue probes
are highly invasive, their use can be regarded as gross
animal experimentation in humans21-23, which should
therefore be abandoned and eventually punished, ra-
ther than being commercially and industrially pro-
moted.
Future prospects
Because a variety of acute intracranial insults (be-
sides brain trauma) may be frequently associated
with combined abnormalities regarding ICP, CPP, and
CEO2, Table 1 shows a broad spectrum of acute intra-
cranial disease processes in which our proposed
monitoring and protocol could also be explored. It
is hoped that this comprehensive, practical, and inex-
pensive monitoring and treatment protocol will also
help lowering mortality rates in acute intracranial
events other than acute severe brain trauma.
Table 1. Indications for arteriojugular monitoring and management.
1 Severe acute brain trauma with suspected or con-
firmed intracranial hypertension;
2 Some forms of nontraumatic intracranial hemorrhage
with suspected or confirmed intracranial hypertension;
3 Hepatic encephalopathy with suspected or confirmed
intracranial hypertension;
4 Uremic encephalopathy with suspected or confirmed
intracranial hypertension;
5 Near-drowning with suspected or confirmed intra-
cranial hypertension;
6 Posthypoxic encephalopathy with suspected or con-
firmed intracranial hypertension;
7 Meningitis or meningoencephalitis with suspected or
confirmed intracranial hypertension;
8 Hypertensive encephalopathy (including eclamptic
encephalopathy) with suspected or confirmed intrac-
ranial hypertension;
9 Septic encephalopathy with suspected or confirmed
intracranial hypertension
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